Lettmann Jason
CHIEF EXECUTIVE OFFICER at ALXO; Director at Ra Pharmaceuticals, Inc.
- Sold, on record
- $13.6M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Aug 17, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- ALXOALX ONCOLOGY HOLDINGS INCCHIEF EXECUTIVE OFFICER
- Ra Pharmaceuticals, Inc.Director
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ALXO490,096 shares
- Ra Pharmaceuticals, Inc.340 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Ra Pharmaceuticals, Inc.Plan not statedOct 31, 2016 2016
Sold 340 shares at $13.00 ($4k)
Lettmann Jason, Director
Sold 0.4% of holdings ($1M position)79,821 shares leftFirst sale on recordFiling
- 2 Form 4 sale ALXOUnusualDec 10, 2021 +1866 days
Sold 145,637 shares at $32.26 ($4.7M)
Lettmann Jason, Director, 10% owner
Sold 33.3% of holdings ($14.1M position)291,758 shares leftFirst sale on recordFiling
- 3 Form 4 sale ALXOUnusualDec 13, 2021 +3 days
Sold 325,377 shares at $27.36 ($8.9M)
Name not stated, Director, 10% owner
Sold 53.2% of holdings ($16.7M position)285,956 shares leftFiling
- 4 Form 4 sale ALXONo planFeb 19, 2025 +1164 days
Sold 2,159 shares at $1.15 ($2k)
Lettmann Jason, CHIEF EXECUTIVE OFFICER
No 10b5-1 planSold 1.3% of holdings ($198k position)170,270 shares leftFirst sale on recordFiling
- 5 Form 4 sale ALXONo planAug 15, 2025 +177 days
Sold 2,382 shares at $0.64 ($2k)
Lettmann Jason, CHIEF EXECUTIVE OFFICER
No 10b5-1 planSold 1.1% of holdings ($138k position)212,888 shares leftFiling
- 6 Form 4 sale ALXONo planMar 19, 2026 +216 days
Sold 12,311 shares at $2.17 ($27k)
Lettmann Jason, CHIEF EXECUTIVE OFFICER
No 10b5-1 planSold 4% of holdings ($664k position)293,609 shares leftFiling
- 7 Form 4 sale ALXONo planAug 17, 2026 +151 days
Sold 2,230 shares at $1.93 ($4k)
Lettmann Jason, CHIEF EXECUTIVE OFFICER
No 10b5-1 planSold 0.8% of holdings ($572k position)294,379 shares left0.9x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (7)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Aug 18, 2026 | ALXO | CHIEF EXECUTIVE OFFICER | Form 4 sale | 2,230 | $4k | 0.8% | No plan | SEC |
| Mar 19, 2026 | Mar 23, 2026 | ALXO | CHIEF EXECUTIVE OFFICER | Form 4 sale | 12,311 | $27k | 4.0% | No plan | SEC |
| Aug 15, 2025 | Aug 19, 2025 | ALXO | CHIEF EXECUTIVE OFFICER | Form 4 sale | 2,382 | $2k | 1.1% | No plan | SEC |
| Feb 19, 2025 | Feb 21, 2025 | ALXO | CHIEF EXECUTIVE OFFICER | Form 4 sale | 2,159 | $2k | 1.3% | No plan | SEC |
| Dec 13, 2021 | Dec 15, 2021 | ALXO | Director, 10% owner | Form 4 sale | 325,377 | $8.9M | 53.2% | Unusual | SEC |
| Dec 10, 2021 | Dec 10, 2021 | ALXO | Director, 10% owner | Form 4 sale | 145,637 | $4.7M | 33.3% | Unusual | SEC |
| Oct 31, 2016 | Oct 31, 2016 | Ra Pharmaceuticals, Inc. | Director | Form 4 sale | 340 | $4k | 0.4% | Plan not stated | SEC |